2359.HK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 Jun 2024 @ 01:04):

Stats
Today's Volume	1.90M
Average Volume	9.42M
Market Cap	127.79B
EPS	HKD0.940 ( 2023-10-31 )
Next earnings date	( HKD0 ) 2024-06-12
Last Dividend	HKD0.989 ( 2023-06-05 )
Next Dividend	HKD0 ( N/A )
P/E	9.76
ATR14	HKD0.0380 (0.11%)

Volume Correlation

Long: 0.17 (neutral)

Short: -0.19 (neutral)

Signal:(52.418) Neutral

WuXi AppTec Co., Ltd. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

WuXi AppTec Co., Ltd. Correlation - Currency/Commodity

-0.44
( neutral )

0.40
( neutral )

0.00
( neutral )

-0.17
( neutral )

0.40
( neutral )

WuXi AppTec Co., Ltd. Financials

Annual	2023
Revenue:	HKD40.34B
Gross Profit:	HKD16.61B (41.18 %)
EPS:	HKD3.27

FY	2023
Revenue:	HKD40.34B
Gross Profit:	HKD16.61B (41.18 %)
EPS:	HKD3.27

FY	2022
Revenue:	HKD39.35B
Gross Profit:	HKD14.68B (37.30 %)
EPS:	HKD3.15

FY	2021
Revenue:	HKD22.90B
Gross Profit:	HKD8.31B (36.28 %)
EPS:	HKD1.820

Financial Reports:

No articles found.

WuXi AppTec Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.989 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

WuXi AppTec Co., Ltd. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.16 - Stable (23.16%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.281	2019-06-17
Last Dividend	HKD0.989	2023-06-05
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	HKD2.45	--
Avg. Dividend % Per Year	0.00%	--
Score	3.2	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.16
Div. Directional Score	8.85	--

Next Divdend (Est)
(2025-03-31)

HKD1.307 Estimate 3.09 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.20

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
2217.HK	Ex Dividend Junior	2023-08-15	Annually	0.00%
1065.HK	Ex Dividend Junior	2023-06-05	Annually	0.00%
0038.HK	Ex Dividend Knight	2023-06-08	Sporadic	0.00%
6812.HK	Ex Dividend Junior	2023-08-04	Sporadic	0.00%
1696.HK	Ex Dividend Knight	2023-08-24	Annually	0.00%
0586.HK	Ex Dividend Junior	2023-06-29	Annually	0.00%
2388.HK	Ex Dividend Knight	2023-09-14	Semi-Annually	0.00%
1209.HK	Ex Dividend Knight	2023-09-12	Semi-Annually	0.00%
0135.HK	Ex Dividend Knight	2023-06-05	Annually	0.00%
8617.HK	Ex Dividend Junior	2023-06-20	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.238	1.500	5.23	7.85	[0 - 0.5]
returnOnAssetsTTM	0.125	1.200	5.83	6.99	[0 - 0.3]
returnOnEquityTTM	0.177	1.500	9.15	10.00	[0.1 - 1]
payoutRatioTTM	0.292	-1.000	7.08	-7.08	[0 - 1]
currentRatioTTM	2.33	0.800	3.36	2.69	[1 - 3]
quickRatioTTM	1.827	0.800	3.96	3.17	[0.8 - 2.5]
cashRatioTTM	1.175	1.500	4.59	6.88	[0.2 - 2]
debtRatioTTM	0.0947	-1.500	8.42	-10.00	[0 - 0.6]
interestCoverageTTM	59.78	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	4.35	2.00	8.55	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.61	2.00	8.70	10.00	[0 - 20]
debtEquityRatioTTM	0.128	-1.500	9.49	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.409	1.000	6.52	6.52	[0.2 - 0.8]
operatingProfitMarginTTM	0.294	1.000	6.12	6.12	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.778	1.000	1.231	1.231	[0.2 - 2]
assetTurnoverTTM	0.525	0.800	9.83	7.87	[0.5 - 2]
Total Score				11.54

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	9.74	1.000	9.12	0	[1 - 100]
returnOnEquityTTM	0.177	2.50	9.45	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.61	2.00	9.13	10.00	[0 - 30]
dividendYielPercentageTTM	3.14	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.35	2.00	8.55	10.00	[0 - 30]
payoutRatioTTM	0.292	1.500	7.08	-7.08	[0 - 1]
pegRatioTTM	0.298	1.500	-1.348	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.321	1.000	4.49	0	[0.1 - 0.5]
Total Score				6.16

WuXi AppTec Co., Ltd. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

WuXi AppTec Co., Ltd.

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.